纽约（法新社肥胖症专栏）12月21日电—据《变态反应，糖尿病及医学研究年鉴》华尔街日报11创刊号一篇媒体报道，舌下减敏麻醉药（SLIT）放射治疗花粉诱发的溃疡过敏全面适度高。“并用SLIT减少百日咳的并发症及抗生素消费，减缓社会经济负担，”那不勒斯Genoa所大学Giovanni PassalacquaDr说是。“先前仍然有强化注射麻醉药减缓社会负担，但这是首次对简单麻醉药（SLIT）完成严格评估的结果。”PassalacquaDr及其同事们对花粉诱发的过敏适度百日咳和糖尿病治果完成研究，评估并用SLIT结合标准规范放射治疗及分开并用标准规范放射治疗的支出及。研究人员媒体报道，SLIT使63.1%的症状症状强化，并预防51.8%的症状消失糖尿病，而分开运用标准规范麻醉药也就是说使23.2%的症状症状强化，预防28.9%的症状消失糖尿病。而且同标准规范放射治疗相比，SLIT的直接及间接要花费仅降低：SLIT症状放射治疗的相比之下要花费少于国际组织儿童教育系统假设的4年内分开抗生素放射治疗要花费，并且少于国际组织政府假设的2年内分开抗生素放射治疗要花费。“SLIT并不能算是强化注射麻醉药的的企业，” PassalacquaDr解释说是，“而是将其作为放射治疗方法的另一选择。它最大的优点在于其最优的简单适度和症状的易接受适度。”“SLIT在美国并未正式运用，尽管一些变态反应专家学者运用它（并且取得了满意的结果），” PassalacquaDr说是。“欧洲情况下完全完全相同，SLIT在很多国际组织之中技术的发展（如那不勒斯，德国，巴伦西亚，巴伦西亚，加的斯，克里特及拉脱维亚）。”当前的问题是SLIT并未想得到FDA的批准，“PassalacquaDr补充道。“受到FDA支持的临床研究正在完成之中，并将会想得到批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma & Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.
编者：紫色幻想
编者： 张靖相关新闻
相关问答
